{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-18T17:18:45.201909+00:00","company":{"ticker":"LABT","cik":2079272,"company_name":"Lakewood-Amedex Biotherapeutics Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"governance_change","fact_key":"c1add010a37a2882c0e1d53ec4ca66cbbcddfc6f","cik":2079272,"ticker":"LABT","company_name":"Lakewood-Amedex Biotherapeutics Inc.","filed_at":"2026-06-17T15:40:39+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-06-19","item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Change to effectuate a 1-for-10 reverse stock split and reduce authorized shares to 12,500,000."},"claim":"Lakewood-Amedex Biotherapeutics Inc.: Filed a Certificate of Change to effectuate a 1-for-10 reverse stock split and reduce authorized shares to 12,500,000 (effective 2026-06-19).","evidence_excerpt":"On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-069512","anchor_url":"https://secwatch.observer/filing/0001213900-26-069512#claim-c1add010a37a2882c0e1d53ec4ca66cbbcddfc6f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/0001213900-26-069512-index.htm"},{"fact_type":"executive_change","fact_key":"27b676567a","cik":2079272,"ticker":"LABT","company_name":"Lakewood-Amedex Biotherapeutics Inc.","filed_at":"2026-04-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-04-24","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Joseph Tucker was appointed as Director at Lakewood-Amedex Biotherapeutics Inc..","evidence_excerpt":"On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001213900-26-048553","anchor_url":"https://secwatch.observer/filing/0001213900-26-048553#claim-27b676567a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2079272/000121390026048553/0001213900-26-048553-index.htm"}]}